HMG-COA还原酶抑制剂对原发性肾病综合征患儿免疫功能高脂血症的干预  

HMG-COA Reductase Inhibitors on the Immune Function of Children with Primary Nephrotic Syndrome of the Hyperlipemia Intervention

作　　者：徐洁平 陈碧珊[1] 骆郁林 

机构地区：[1]广东省汕头市第二人民医院药剂科,广东汕头515001

出　　处：《中国医药指南》2015年第13期8-9,共2页Guide of China Medicine

摘　　要：目的探讨辛伐他汀(HMG-COA还原酶抑制剂)治疗原发性肾病综合征患儿免疫功能高脂血症的临床疗效。方法选取80例合并免疫功能高脂血症的原发性肾病综合征患儿作为研究对象。结果两组患者治疗前的CRP、BUN、SCr、24 h尿蛋白、TG、TC水平比较,差异均不具有统计学意义,P>0.05;治疗后,两组患者的各项指标均较治疗前有一定降低,均明显低于对照组,P<0.05。结论在原发性肾病综合征患儿的临床治疗中,应用辛伐他汀,能有效降低尿蛋白及血脂水平,具有重要的应用价值。Objective To study the simvastatin（HMG COA reductase inhibitors） treating primary nephrotic syndrome in children with the clinical curative effect of immune function of the hyperlipemia. Methods Choose 80 cases of merger of immune function of the hyperlipemia children with primary nephrotic syndrome as the research object. Results Ttwo groups of patients before treatment of CRP, BUN, SCr, 24 h urinary albumin, TG, TC level, differences were not statistically significant, P〈0.05; All the indexes after treatment, two groups of patients compared with before treatment must be reduced, were significantly lower than the control group, P〈0.05）. Conclusions In clinical treatment of children with primary nephrotic syndrome, the application of simvastatin, can effectively reduce the urine protein and lipid levels, has important application value.

关 键 词：免疫功能高脂血症 原发性肾病综合征 辛伐他汀 

分 类 号：R692[医药卫生—泌尿科学] R589[医药卫生—外科学]